[go: up one dir, main page]

NO20015547L - Fremgangsmåte for hemisyntese av forbindelser og nye forbindelser - Google Patents

Fremgangsmåte for hemisyntese av forbindelser og nye forbindelser

Info

Publication number
NO20015547L
NO20015547L NO20015547A NO20015547A NO20015547L NO 20015547 L NO20015547 L NO 20015547L NO 20015547 A NO20015547 A NO 20015547A NO 20015547 A NO20015547 A NO 20015547A NO 20015547 L NO20015547 L NO 20015547L
Authority
NO
Norway
Prior art keywords
compounds
hemisynthesis
new
new compounds
Prior art date
Application number
NO20015547A
Other languages
English (en)
Other versions
NO20015547D0 (no
NO322016B1 (no
Inventor
Carmen Cuevas
Marta Perez
Andres Francesch
Carolina Fernandez
Jose Luis Chicharro
Pilar Gallego
Maria Zarzuelo
Fernando De La Calle
Ignacio Manzanares
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9911345.8A external-priority patent/GB9911345D0/en
Priority claimed from GBGB9918178.6A external-priority patent/GB9918178D0/en
Priority claimed from GBGB9923632.5A external-priority patent/GB9923632D0/en
Priority claimed from GB0001063A external-priority patent/GB0001063D0/en
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of NO20015547D0 publication Critical patent/NO20015547D0/no
Publication of NO20015547L publication Critical patent/NO20015547L/no
Publication of NO322016B1 publication Critical patent/NO322016B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20015547A 1999-05-14 2001-11-13 Anvendelse av utgangsmaterialer,fremgangsmate for hemisyntese av forbindelser og nye forbindelser NO322016B1 (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9911345.8A GB9911345D0 (no) 1999-05-14 1999-05-14
GBGB9918178.6A GB9918178D0 (en) 2000-05-15 1999-08-02 Synthetic methods
GBGB9923632.5A GB9923632D0 (en) 1999-10-06 1999-10-06 Hemisynthetic process towards ecteinascidin and phtalscidin compounds
GB0001063A GB0001063D0 (en) 2000-01-17 2000-01-17 Hemisynthetic process towards ecteinascidin and phtalascidin
PCT/GB2000/001852 WO2000069862A2 (en) 1999-05-14 2000-05-15 Hemisynthetic method and intermediates thereof

Publications (3)

Publication Number Publication Date
NO20015547D0 NO20015547D0 (no) 2001-11-13
NO20015547L true NO20015547L (no) 2002-01-14
NO322016B1 NO322016B1 (no) 2006-08-07

Family

ID=42632476

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20015547A NO322016B1 (no) 1999-05-14 2001-11-13 Anvendelse av utgangsmaterialer,fremgangsmate for hemisyntese av forbindelser og nye forbindelser
NO20025186A NO328301B1 (no) 1999-05-14 2002-10-29 Fremgangsmate for syntese av en ecteinascidinforbindelse

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20025186A NO328301B1 (no) 1999-05-14 2002-10-29 Fremgangsmate for syntese av en ecteinascidinforbindelse

Country Status (29)

Country Link
US (3) US7241892B1 (no)
EP (1) EP1185536B1 (no)
JP (1) JP4445136B2 (no)
KR (1) KR100834601B1 (no)
CN (3) CN1229382C (no)
AR (1) AR035842A1 (no)
AT (1) ATE283273T1 (no)
AU (2) AU775580B2 (no)
BG (1) BG65896B1 (no)
BR (3) BRPI0010559B8 (no)
CA (2) CA2372058C (no)
CY (1) CY1108095T1 (no)
CZ (3) CZ303536B6 (no)
DE (1) DE60016209T2 (no)
DK (1) DK1185536T3 (no)
ES (2) ES2233367T3 (no)
HU (1) HU230646B1 (no)
MX (1) MXPA01011631A (no)
MY (1) MY130271A (no)
NO (2) NO322016B1 (no)
NZ (1) NZ515424A (no)
PL (1) PL226890B1 (no)
PT (1) PT1185536E (no)
RU (1) RU2237063C9 (no)
SI (2) SI1185536T1 (no)
SK (2) SK287835B6 (no)
TR (1) TR200103273T2 (no)
UA (1) UA75333C2 (no)
WO (3) WO2000069862A2 (no)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE289810T1 (de) 1998-05-11 2005-03-15 Pharma Mar Sa Ecteinascidinderivate
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MY130271A (en) 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
US7919493B2 (en) * 2000-04-12 2011-04-05 Pharma Mar, S.A. Anititumoral ecteinascidin derivatives
BRPI0110024B8 (pt) 2000-04-12 2021-05-25 Pharma Mar Sa derivados de ecteinascidina antitumorais, composição farmacêutica que os compreende e uso dos mesmos
JP4942900B2 (ja) * 2000-05-15 2012-05-30 ファルマ・マール・ソシエダード・アノニマ エクチナサイジン化合物の製造のための合成方法
US7420051B2 (en) 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
AU3956502A (en) 2000-11-03 2002-05-27 Harvard College Saframycins, analogues and uses thereof
AU2002212499B2 (en) * 2000-11-06 2006-11-02 Pharma Mar, S.A. Compositions for antitumour treatment containing ecteinascidin 743
GB0117402D0 (en) 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0119243D0 (en) * 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
US20050004018A1 (en) * 2001-10-19 2005-01-06 Jose Jimeno Use of antitumoral compound in cancer therapy
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB0229793D0 (en) * 2002-12-20 2003-01-29 Pharma Mar Sa The gene cluster involved in safracin biosynthesis and its uses for genetic engineering
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
US7183054B2 (en) 2003-06-03 2007-02-27 President And Fellows Of Harvard College Assay for identifying biological targets of polynucleotide-binding compounds
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
CA2544320A1 (en) 2003-11-13 2005-06-02 Pharma Mar, S.A.U. Method of treating cancer using a combination comprising et-743 and 5-fluorouracil
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
CN1897949A (zh) * 2003-11-14 2007-01-17 马尔药品公司 包含使用et－743和紫杉醇来治疗癌症的联合疗法
US20080242670A2 (en) * 2004-09-29 2008-10-02 Pharma Mar S.A., Sociedad Unipersonal Anti-Inflammatory Agents
RU2359700C2 (ru) * 2004-10-26 2009-06-27 Фарма Мар С.А., Сосьедад Униперсональ Пегилированный липосомальный доксорубицин в комбинации с эктеинасцидином 743 (ecteinescidin 743)
WO2006046079A1 (en) * 2004-10-29 2006-05-04 Pharma Mar S.A., Sociedad Unipersonal Formulations comprising ecteinascidin and a disaccharide
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
KR100712667B1 (ko) 2006-04-11 2007-05-02 재단법인서울대학교산학협력재단 신규한 디아자 헤테로고리 유도체 및 그의 고체상 제조방법
GB0708691D0 (en) * 2007-05-04 2007-06-13 Pharma Mar Sa Anticancer treatments a
US20090076017A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched trabectedin
EP2201141A1 (en) * 2007-10-19 2010-06-30 Pharma Mar S.A. Prognostic molecular markers for et-743 treatment
MX2010012501A (es) * 2008-05-16 2010-12-20 Pharma Mar Sa Terapia de combinacion con un alcaloide antitumoral.
RU2519750C2 (ru) * 2008-05-16 2014-06-20 Фарма Мар, С.А. Способы лечения множественной миеломы
WO2011048210A1 (en) 2009-10-22 2011-04-28 Pharma Mar, S.A. PDGFR-α AS RESPONSE MARKER FOR PM00104 TREATMENT
CN103038240A (zh) * 2010-05-25 2013-04-10 法马马有限公司 制备海鞘素化合物的合成方法
PL2786754T3 (pl) 2010-11-12 2019-07-31 Pharma Mar S.A. Leczenie skojarzone inhibitorem mitozy
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
CN107739387B (zh) * 2017-10-16 2020-01-03 上海皓元生物医药科技有限公司 一种制备曲贝替定的关键中间体化合物的方法
CN109912629B (zh) * 2017-12-13 2021-12-24 浙江中科创越药业有限公司 天然产物Trabectedin的制备
TWI824043B (zh) 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物
CN111518110B (zh) 2019-02-01 2023-11-03 博瑞生物医药（苏州）股份有限公司 一种海鞘素化合物及其中间体的制备方法
CN111620792B (zh) * 2019-02-28 2023-01-03 兰州大学 一种n,n-二取代氰基甲酰胺的合成方法
JOP20220118A1 (ar) 2019-11-21 2023-01-30 Pharma Mar Sa طرق لعلاج سرطان الرئة للخلايا الصغيرة بصيغ من لوربينيكتيدين
CN116217584A (zh) * 2021-12-06 2023-06-06 南通诺泰生物医药技术有限公司 Et743及其中间体的光催化合成方法
CN120641094A (zh) * 2023-01-17 2025-09-12 艾德赛瑞思股份有限公司 海鞘素衍生物抗体药物缀合物
WO2025077996A1 (en) 2023-10-09 2025-04-17 Pharma Mar, S.A. Synthetic process for the manufacture of ecteinascidin compounds
WO2025233522A1 (en) 2024-05-10 2025-11-13 Pharma Mar, S.A. Synthetic process for an ecteinascidin

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2461995A1 (fr) * 1979-07-20 1981-02-06 Lcc Cice Cie Europ Compo Elect Transducteur magneto-electrique pour systeme d'enregistrement magnetique, et systeme d'enregistrement comportant un tel transducteur
JPS59225189A (ja) 1983-06-03 1984-12-18 Shionogi & Co Ltd キノナミン誘導体およびその製造法
JPS6054386A (ja) * 1983-09-02 1985-03-28 Yoshitomi Pharmaceut Ind Ltd サフラシン誘導体
JPS6084288A (ja) 1983-10-13 1985-05-13 Shionogi & Co Ltd シアノキノナミンアセテ−ト類およびその製造法
US5149804A (en) 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
EP0309477B1 (en) 1986-06-09 1991-11-06 The Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759a, 759b and 770
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
SG50747A1 (en) * 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
WO1999051238A1 (en) 1998-04-06 1999-10-14 The Board Of Trustees Of The University Of Illinois Semi-synthetic ecteinascidins
ATE289810T1 (de) 1998-05-11 2005-03-15 Pharma Mar Sa Ecteinascidinderivate
US6124292A (en) 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY130271A (en) 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
CA2397597A1 (en) 2000-01-19 2001-07-26 The Trustees Of Columbia University In The City Of New York Compounds of the saframycin-ecteinascidin series, uses, and synthesis thereof
BRPI0110024B8 (pt) 2000-04-12 2021-05-25 Pharma Mar Sa derivados de ecteinascidina antitumorais, composição farmacêutica que os compreende e uso dos mesmos
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.

Also Published As

Publication number Publication date
CN100475822C (zh) 2009-04-08
CA2372058A1 (en) 2000-11-23
SK287879B6 (sk) 2012-02-03
CZ20014102A3 (cs) 2002-06-12
JP2002544280A (ja) 2002-12-24
CA2406095A1 (en) 2001-11-22
CN1211386C (zh) 2005-07-20
WO2001087894A1 (en) 2001-11-22
NO328301B1 (no) 2010-01-25
BR0110801A (pt) 2003-02-11
TR200103273T2 (tr) 2002-04-22
SK16502001A3 (sk) 2002-06-04
BRPI0110801B1 (pt) 2018-02-27
EP1185536A2 (en) 2002-03-13
SI1185536T1 (en) 2005-06-30
NZ515424A (en) 2004-06-25
KR100834601B1 (ko) 2008-06-02
DE60016209T2 (de) 2005-12-15
JP4445136B2 (ja) 2010-04-07
CN1441805A (zh) 2003-09-10
BRPI0110801B8 (pt) 2021-05-25
US20080045713A1 (en) 2008-02-21
ES2233367T3 (es) 2005-06-16
RU2237063C9 (ru) 2008-10-10
SK287835B6 (sk) 2011-12-05
BR0110443A (pt) 2003-04-08
MXPA01011631A (es) 2002-07-30
KR20020021636A (ko) 2002-03-21
AU775580B2 (en) 2004-08-05
BG107301A (bg) 2003-07-31
WO2001087895A1 (en) 2001-11-22
CA2372058C (en) 2010-10-26
NO20025186L (no) 2003-01-14
ES2231486T3 (es) 2005-05-16
BRPI0010559B8 (pt) 2021-05-25
BRPI0110443B8 (pt) 2021-05-25
CZ20023751A3 (en) 2004-05-12
PL226890B1 (pl) 2017-09-29
DK1185536T3 (da) 2005-04-04
CN1360588A (zh) 2002-07-24
WO2000069862A2 (en) 2000-11-23
AU4597300A (en) 2000-12-05
US7241892B1 (en) 2007-07-10
HU230646B1 (hu) 2017-05-29
RU2237063C2 (ru) 2004-09-27
HUP0201188A2 (en) 2002-07-29
CZ304966B6 (cs) 2015-02-18
PL353002A1 (en) 2003-09-22
SI1287004T1 (sl) 2005-12-31
UA75333C2 (uk) 2006-04-17
MY130271A (en) 2007-06-29
PT1185536E (pt) 2005-04-29
HK1047432A1 (en) 2003-02-21
DE60016209D1 (de) 2004-12-30
US20040002602A1 (en) 2004-01-01
CZ303536B6 (cs) 2012-11-21
BR0010559A (pt) 2002-07-02
BRPI0110443B1 (pt) 2018-06-26
NO20025186D0 (no) 2002-10-29
US7524956B2 (en) 2009-04-28
EP1185536B1 (en) 2004-11-24
CZ304973B6 (cs) 2015-02-25
SK15272002A3 (sk) 2003-06-03
AU5649601A (en) 2001-11-26
NO20015547D0 (no) 2001-11-13
BG65896B1 (bg) 2010-04-30
AR035842A1 (es) 2004-07-21
ATE283273T1 (de) 2004-12-15
WO2000069862A3 (en) 2001-03-22
NO322016B1 (no) 2006-08-07
CY1108095T1 (el) 2014-02-12
CA2406095C (en) 2010-02-16
BRPI0010559B1 (pt) 2016-08-30
CN1229382C (zh) 2005-11-30
CZ20023746A3 (cs) 2003-04-16
CN1440414A (zh) 2003-09-03

Similar Documents

Publication Publication Date Title
NO20015547L (no) Fremgangsmåte for hemisyntese av forbindelser og nye forbindelser
NO20014960L (no) Nye fremgangsmåter for behandling
NO20015156D0 (no) 5-pyridyl-1,3-Azol forbindelser, fremgangsmåte for produksjon av de samme og deres anvendelse
NO20000227L (no) Krystallmodifikasjon av et N-fenyl-2-pyrimidinaminderivat, fremgangsmåte for dens fremstilling og dens anvendelse
NO984161D0 (no) Fremgangsmåte og innretning for fremstilling av etalisk jern
NO20014950L (no) Nye behandlingsmetoder
NO20015542D0 (no) Fremgangsmåte for fremstilling og anvendelse av N- desmetylzopikloner
NO20012963D0 (no) Fremgangsmåte for fremstilling av 3-alkanoylindoler og 3- alkylindoler
NO991382L (no) Mellomprodukter og fremgangsmÕte for fremstilling av olanzapin
NO20013880D0 (no) Matriks og fremgangsmate for fremstilling av polyolefin
NO20021124L (no) Fremgangsmåte for fremstilling av benzoksazinderivater og mellomprodukter derfor
NO20032440D0 (no) Fremgangsmåte for fremstillingen av iopamidol og de nye intermediater deri
NO994505L (no) Forbedret fremgangsmåte for fremstilling av tiazolidindioner og nye tiazolidindioner
NO20014222D0 (no) Fremgangsmåte for behandling av COPD
NO20001387L (no) FremgangsmÕte for syntese av kinolinderivater
NO20024058D0 (no) Fremgangsmåte for fremstilling av et oksazolyletanolderivat
NO20014005L (no) Fremgangsmåte og anlegg for hygienisering og törking av organisk avfall
NO20012099L (no) Fremgangsmåte for fremstilling av 4-arylpiperidin-3- karbinoler og beslektede forbindelser
NO20014077L (no) Fremgangsmåte for krystallisering av N-(4-trifluormetylfenyl)- 5-metyl-isoksazol-4-karboksamid
NO20023577L (no) Fremgangsmåte for fremstilling av acetyl-amidinofenylalanyl- cykloheksylglycyl-pyridinioalaninamider
NO20000805D0 (no) Fremgangsmåte for fremstilling av organiske azider
NO20006383D0 (no) Fremgangsmåte for behandling
NO20030587D0 (no) Fremgangsmåte til fremstilling av diskodermolid og analoger derav
PL339287A1 (en) Method of obtaining heterocyclic compounds and novel intermediate compounds
NO20022157D0 (no) Fremgangsmåte for behandling av medikamentavhengighet

Legal Events

Date Code Title Description
MK1K Patent expired